US Pharma MarketingNovartis gives infectious disease docs a boost with antibiotic approval
Novartis quietly wins FDA nod to bring decades-old antibiotic Lamprene back to the US market, easing access. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug…
There is some good news in the world of antibiotics.
Novartis quietly snagged supplemental FDA approval for its drug Lamprene over the summer, transitioning a decades-old leprosy drug to the commercial market, which may boost ...
Source: Endpoints News